The purpose of this FOA is to provide investigators working on the development of novel therapeutic products for HIV and HIV-associated co-infections (hepatitis B virus, hepatitis C virus, and Mycobacterium tuberculosis) with a mechanism to request NIAID DAIDS preclinical services to fill gaps in their product development efforts and facilitate the advancement of promising therapeutics from bench to clinics.
Deadlines:
-
Letter of Intent Due Date(s): 30 days prior to the application due date
-
AIDS Application Due Dates: Sep 1, 2022; Jan 17, 2023; Sep 1, 2023; Jan 17, 2024; Sep 1, 2024; Jan 17, 2025
PAR-22-185 Expiration Date January 18, 2025
A separate application is required for each service area (A-D). Applicants may submit more than one application per each service area provided they are distinct.